CytRx (CYTR) Commences Common Offering
Tweet
Share
E-mailGet Alerts CYTR Hot Sheet
Join SI Premium – FREE
CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, announced today its intention, subject to market and other conditions, to commence a public offering of its common stock. CytRx intends to use the net proceeds from the offering to fund clinical development of its drug candidates aldoxorubicin and tamibarotene, and for general corporate purposes, which may include working capital, capital expenditures, research and development and other commercial expenditures.
Aegis Capital Corp. is acting as the sole book-running manager for the offering.
Aegis Capital Corp. is acting as the sole book-running manager for the offering.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
- MAIA Biotechnology (MAIA) files $150M mixed shelf
- Noodles & Company (NDLS) files $100M mixed shelf
Create E-mail Alert Related Categories
Equity OfferingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
